Trial Master File: An Inspection Narrative, Not a Cabinet

At a glance

• The TMF is the contemporaneous evidence that a trial was conducted per protocol and GCP. Read it as a narrative an inspector follows, not a cabinet you stuff documents into.
• The test for any document is simple: does it help prove the trial was run correctly and the data are reliable? If yes, it belongs; if no, it does not.
• TMF and eTMF are the same thing in different media. Regulation does not differentiate paper, electronic, or hybrid; the requirements are identical.
• The DIA TMF Reference Model is a widely used industry standard for structuring a TMF. It is not a regulation, and adopting it is not a legal requirement.
• “Inspection-ready” means complete, legible, contemporaneous, and accurate, set up at the start, filed on time, and retained for the required period.

Most TMF guides list document types but rarely explain the purpose of each, conflate the DIA TMF Reference Model with the regulatory requirements behind it, and gloss over the paper-to-electronic transition and who actually owns what. This guide reframes the TMF as an inspection narrative: every essential document earns its place by proving part of the conduct-and-data-quality story. It covers the definition, TMF versus eTMF, the Reference Model (and its true status), essential documents grouped by what they prove, sponsor TMF versus investigator site file, setup and retention, and what inspection-ready really means. The downloadable checklist and eTMF software selection have their own guides; this is the concept hub.

What is a trial master file (TMF)?

A TMF is the collection of essential documents that lets people run and verify a trial. EMA defines it as the collection of essential documents used by sponsors, CROs, and investigators to manage the trial and by monitors, auditors, and inspectors to review and verify whether the trial was conducted in line with applicable regulatory requirements and GCP (EMA TMF, §2). The deeper framing, the one that should drive every filing decision, is reconstruction: the documentation should be sufficient to reconstruct the activities undertaken and the decisions and justifications made, and should collectively confirm compliance with the protocol and GCP without additional explanation from staff (EMA TMF, §2). ICH E6(R3) says the same of essential records: they permit and contribute to the evaluation of the conduct of a trial and the reliability of the results, and are used in investigator and sponsor oversight, by auditors, and during inspections (ICH E6(R3) Appendix C.1).

That is why “inspection narrative” is the right mental model. An inspector reads the TMF to answer one question, was this trial run correctly, and each document is a sentence in that story.

TMF vs eTMF: paper, electronic, and hybrid

There is no regulatory distinction between a paper TMF and an electronic one. EMA is explicit that the legislation does not differentiate between paper and electronic TMFs, so all basic requirements are the same for both formats or for a hybrid combination (EMA TMF, §2). Whatever the medium, the TMF must provide for document identification, version history, search, and retrieval, and be archived so it is readily available and directly accessible upon request to the competent authorities (EMA TMF, §2).

Why most teams have moved to an eTMF (and what doesn’t change)

Electronic TMFs make search, access control, and audit-trailing easier, which is why adoption has grown. But the requirements do not relax. EMA expects an eTMF to have user accounts and secure passwords, document or system locking to prevent changes, regular backup, periodic test retrieval, an audit trail capturing date, time, and user for creation, deletion, and changes, and role-based permissions, and to be validated to demonstrate the functionality is fit for purpose (EMA TMF, §4.1.2). Going electronic changes the tooling, not the obligations.

The DIA TMF Reference Model: zones, sections, artifacts

The DIA TMF Reference Model is an industry standard, published by DIA, that organizes essential documents into zones, sections, and artifacts to give teams a common structure. It is genuinely useful as a structuring convention, and many eTMF systems are built around it.

Is the Reference Model mandatory?

No. This is the distinction the ranking pages blur. The Reference Model is an industry standard, not a regulation, and adopting it is not a legal requirement. What is required is that the TMF contain the essential documents and permit reconstruction and verification of the trial (EMA TMF, §3.5.1), and that there be a suitable overall index or table of contents so the location of essential documents can be traced (EMA TMF, §3.4). The Reference Model is one good way to satisfy that indexing expectation; it is a means, not the mandate. Use it because it helps, not because a regulator requires it.

Essential documents and why each one belongs (grouped by what they prove)

Essential documents are defined by function: those that individually and collectively permit evaluation of the conduct of a trial and the quality of the data produced (EMA TMF, §3.5.1). Grouping them by what they prove makes the “narrative” concrete:

• Proof the trial was ethical and authorized: ethics committee/IRB approvals, regulatory authorisations, informed consent forms. These prove participants were protected and the trial was permitted.
• Proof the trial had a sound, controlled plan: protocol and amendments, investigator’s brochure, and the superseded versions retained to show how the plan evolved (EMA TMF, §3.5.2).
• Proof the trial was conducted as planned: monitoring records, safety reports, delegation logs, and the correspondence needed to reconstruct key decisions (EMA TMF, §3.5.3).
• Proof the data are reliable: data management documentation (data management plan, data validation plan), statistics documentation (statistical analysis plan), and trial-specific system validation records, all named by EMA as essential (EMA TMF, §3.5.1).

Crucially, the essential-document list is not a fixed checklist. EMA states the ICH GCP list should not be used as a definitive checklist and is not exhaustive, and that teams should include any documentation that facilitates reconstructing and evaluating the trial, while a risk-proportionate approach may justify reducing some documentation with the justification documented (EMA TMF, §3.5.1).

Sponsor TMF vs Investigator Site File: who owns what

There is one TMF per trial, in two parts. EMA describes it as usually composed of a sponsor TMF held by the sponsor and an investigator TMF, often called the investigator site file (ISF), held by the site, with certain documents deliberately segregated, the subject identification code list in the investigator TMF only, the master randomisation list in the sponsor TMF only (EMA TMF, §3.1). The investigator/institution is responsible for and must retain control of the essential records it generates (ICH E6(R3) §2.12.11). Documents containing direct identifiers of participants, such as the identification code list, source documents, and signed consent forms, stay under the sole control of the investigator/institution for data-privacy reasons (EMA TMF, §4.1.3). When a CRO is used, the sponsor remains responsible and keeps oversight and access (EMA TMF, §3.2).

Setup, contemporaneous filing, and retention timelines

A TMF is not assembled at the end; it is built as you go. EMA expects the TMF, both sponsor and investigator parts, to be established at the beginning of the trial (EMA TMF, §3.1), and documents to be filed in a timely manner during conduct, which is how EMA reads the requirement that the TMF contain the essential documents “at all times” (EMA TMF, §3.5.4). On retention, periods are set by law; under the EU Clinical Trials Regulation the sponsor and investigator shall archive the TMF for at least 25 years after the end of the trial unless other law requires longer, with subject medical files archived per national law (EMA TMF, §6.3). Confirm the requirement that applies to your specific trial.

What “inspection-ready” actually means

Inspection-ready is a defined standard, not a vibe. The TMF must be complete, legible, and accurate (EMA TMF, §2), kept contemporaneous through timely filing (EMA TMF, §3.5.4), and stored so it remains complete and legible throughout retention and is readily available to the authorities upon request (EMA TMF, §4.1.1). To stay there, EMA expects risk-based quality checks confirming all essential documents are present, filed in the right place, added on time, correctly indexed, access-controlled, and (for an eTMF) audit-trail reviewed (EMA TMF, §4.2). At the document level, where copies replace originals they must be certified copies, verified or generated through a validated process to be exact copies with the same content and context as the original (EMA TMF, §5.1). This is ALCOA thinking applied to the document layer: attributable, legible, contemporaneous, accurate, and available.

A note on boundaries: TrialTrack handles clinical project management, not eTMF document storage. It is not an eTMF and does not hold the TMF. If you need to store and manage TMF documents, that is a different category of system; for selecting one, see the eTMF software guide.

The bottom line

Treat the TMF as the contemporaneous evidence that your trial was run correctly, and every filing decision gets easier: keep what proves the conduct-and-data story, organized so an inspector can follow it. Paper or electronic, the requirements are identical. The DIA TMF Reference Model is a helpful industry standard, not a legal mandate. Build the file from the start, file contemporaneously, retain for the required period, and QC for completeness. Do that, and the TMF reads as a clean narrative rather than a cabinet someone has to explain.

Sources

• ICH E6(R3) Good Clinical Practice
• EMA Guideline on the content, management and archiving of the clinical trial master file (2018)